Anti-angiogenic therapies, via pharmacological inhibition of Vascular Endothelial Growth Factor A (VEGF-A), have been shown to be highly effective in the treatment of both neoplastic conditions and various eye diseases, including neovascular age-related macular degeneration (a major cause of blindness in the developed world), diabetic macular oedema, retinal vein occlusion and myopic choroidal neovascularisation [1] [2,3] [4] [5] [6]. Here, VEGFA is linked to retinal vein occlusion.